Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
mRNA-1469 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| mRNA-1469 Dose Level 1 | EXPERIMENTAL | Participants will receive 1 injection of mRNA-1469 at Dose Level 1 on Day 1. |
| Placebo Matching Dose Level 1 | PLACEBO_COMPARATOR | Participants will receive 1 injection of Placebo matching Dose Level 1 on Day 1. |
| mRNA-1469 Dose Level 2 | EXPERIMENTAL | Participants will receive 1 injection of mRNA-1469 at Dose Level 2 on Day 1. |
| Placebo Matching Dose Level 2 | PLACEBO_COMPARATOR | Participants will receive 1 injection of Placebo matching Dose Level 2 on Day 1. |
| mRNA-1469 Dose Level 3 | EXPERIMENTAL | Participants will receive 1 injection of mRNA-1469 at Dose Level 3 on Day 1. |
| Placebo Matching Dose Level 3 | PLACEBO_COMPARATOR | Participants will receive 1 injection of Placebo matching Dose Level 3 on Day 1. |
| Name | Type | Description |
|---|---|---|
| mRNA-1469 | BIOLOGICAL | Sterile liquid for injection |
| Placebo | BIOLOGICAL | Sterile liquid for injection |
Key Inclusion Criteria: * In good general health or with stable chronic medical conditions, as determined by medical evaluation including medical history, physical examination, and laboratory tests. * Body mass index within the range 18.5 to 39 kg/m2 (inclusive). * Female participants of childbeari...
mRNA-1469 is an investigational mRNA vaccine developed by Moderna, Inc. (ticker MRNA) for the prevention of Ebola-Bundibugyo Virus Disease, also known as Ebola-BDBV. It is in Phase 1 clinical development and is designed to be given to healthy adult volunteers to prevent infection with the Bundibugyo strain of Ebola virus.
mRNA-1469 is being developed to prevent Ebola-Bundibugyo Virus Disease (Ebola-BDBV) in healthy adults. It is a preventive vaccine candidate, not a treatment for people already infected. The Phase 1 study is evaluating whether the vaccine is safe and generates an immune response against the Bundibugyo virus.
mRNA-1469 is developed by Moderna, Inc., which trades on the Nasdaq under the ticker MRNA. Moderna is running the Phase 1 clinical program for the vaccine candidate, which is being studied in Canada in healthy adult participants aged 18 years and older.
mRNA-1469 is in Phase 1 clinical development. It is an investigational vaccine candidate and has not been approved by the FDA or any other regulatory agency. One Phase 1 trial is currently active, and no trials of mRNA-1469 have been completed to date.
mRNA-1469 is being studied in one Phase 1 trial, NCT07737717, titled a study to investigate the safety, reactogenicity, and immunogenicity of mRNA-1469 vaccine to prevent Ebola-Bundibugyo Virus Disease in healthy adult participants. The trial is active but not recruiting, is placebo-controlled and double-blind, and has enrolled 84 participants in Canada.
The Phase 1 trial of mRNA-1469, NCT07737717, is a randomized, double-blind, placebo-controlled study enrolling 84 healthy adult participants of all sexes, aged 18 years and older, in Canada. It is assessing safety, reactogenicity, and immunogenicity of the vaccine candidate against Ebola-Bundibugyo Virus Disease. The trial is active and no longer recruiting.